About

ADVANZ PHARMA® is a global pharmaceutical company that’s committed to helping patients lead healthier, better lives by enabling patients and healthcare providers to access high-quality, niche, established medicines. We do this by revitalising and innovating niche, established medicines that without our focus, may otherwise not be available to patients.

Over the many years we have been supplying medicines, we have built a commercial platform across over 90 countries, providing a portfolio of over 200 niche established medicines safely and effectively all to the highest possible quality standard – we are the first pharma company in the world to achieve an ISO 37001 accreditation for our comprehensive compliance management system.

Our Locations —

  • London—

    UK

  • Dublin—

    Ireland

  • Sydney—

    Australia

  • Mumbai—

    India

  • Helsingborg—

    Sweden

  • USA—

    Chicago

London—

UK

Home to our Global Head Office, London is where our Executive Leadership Team is based along with our corporate and operational functions. In total, we have over 100 employees here.

Close ×
Dublin—

Ireland

We have over 10 employees in Dublin who make up our Global Supplier Alliance Management and Ireland Commercial teams.

Close ×
Sydney—

Australia

Our Australasian office is based in Sydney, Australia. It’s where we serve Australia, New Zealand and the Pacific Island countries from. Our 25 employees here work across Business Development, Finance, Regulatory Affairs, Supply Chain and Sales.

Close ×
Mumbai—

India

Shared Service Centre and India Management Team

Close ×
Helsingborg—

Sweden

Business Development, Finance, Quality, Regulatory Affairs, Supply Chain and Sales

Close ×
USA—

Chicago

Clinical Affairs, Commercial, Regulatory, Quality and Finance, legal and supply chain

Close ×

People & Culture

The success of any company is driven by its people. We are no different. Our teams are made up of people who come from all walks of life and backgrounds, and thrive in an environment where diversity is celebrated but where we are all united by the same passion, to help patients live healthier, better lives.

  • Progressive & Dynamic —

    ADVANZ PHARMA is a progressive and dynamic company, that relies upon the skills of our high calibre teams. We seek to develop and attract the very best talent from across our industry and beyond.

  • Unique, Collaborative & Flexible —

    ADVANZ PHARMA provides a unique culture and a collaborative and flexible working environment that aims to help our people operate at the very best of their ability.

Ready to join?

Help people lead better lives with medicines, that without our focus, may not be available.

View Careers

Our Values

Our brand essence, ‘beyond fulfilment’ means to go beyond what’s expected to deliver the best possible service or solution. Our values embody the ethos of our company and the traits we look for in our people.


Global Teams

We work together, combining the intellectual power of our global, multicultural workforce to find ways to improve the lives of patients.


Entrepreneurial

We don’t sit back. We constantly strive to create new opportunities that deliver value.


Decision Making

We empower our people to use good judgement to make the right choices, enabling them to grow within the company.


Openness

We believe in open and transparent relationships, both internally and externally. We aim to be accessible to our partners, customers and patients; we strive to deliver the best possible service.


Integrity

We insist on the highest ethical behaviour in all aspects of our work. We operate in a highly complex and competitive environment, but we always aim to do what’s right for the healthcare systems and patients we serve.


Our Commitment —

  • Image for Highest Ethical Standards

    Highest Ethical Standards

    To serve the needs of patients and healthcare providers across the world by operating at the highest ethical standards in all aspects of our work.
    Learn more
  • Image for Safe and Effective

    Safe and Effective

    We are committed to providing medicines safely and effectively, all to the highest quality standards.
    Learn more
  • Image for Accreditation

    Accreditation

    We were re-accredited to BS 10500 in 2017 and in November 2018 we became the first pharma company in the world to achieve ISO37001 accreditation for our comprehensive compliance management
    Learn more
  • Image for Open, Transparent and Collaborative

    Open, Transparent and Collaborative

    We aspire to be open, transparent and collaborative in all our relationships and believe in the power of partnership to build trust and inspire better solutions.
    Learn more

Our Portfolio

At ADVANZ PHARMA® we supply over 200 niche generic and established branded medicines in a number of key therapeutic areas – some of which are the fastest growing worldwide.


Our therapy areas include:

  • Endocrinology
  • Ophthalmology
  • Urology
  • Anti-Infectives
  • Pain Management
  • Central Nervous System disorders
  • Intensive Care medicines.

We have successfully expanded our portfolio through targeted development, product in-licensing and acquisition. We continue to work closely with our partners to add value through innovation to strength, formulation and presentation.

On many of our core products, we have worked hard to achieve a dual sourcing strategy, ensuring our medicines can be delivered with confidence into local markets.

  • Our purpose is to help patients lead healthier, better lives by revitalising and innovating niche established medicines that, without our focus, may otherwise not be available.

    But this is not always easy – either because the divestor company has discontinued the manufacture of a medicine and an alternative manufacturer needs to be found or a medicine was originally developed several decades ago which means it can be difficult to manufacture without significant investment to bring it up to date in line with current regulatory requirements.

  • Our experience of supplying and developing niche established medicines for decades means we have a rich heritage of acquiring and investing in these valuable medicines through targeted development, product in-licensing and acquisition to bring them to more markets or by improving product formulation and strength to optimise treatment so that patients can continue to use them for years to come.

  • Bringing medicines to a wider market

    Over the last 15 years, we have acquired more than 15 legacy brands for our international markets and approx. 10 brands for the US market meaning more patients are able to continue to access them.

    Medicines we have revitalized or optimized

    Over the last 10 years, we have worked across 20 initiatives to optimise or revitalize medicines to enhance patient care and provide greater choice.

  • We serve the needs of patients and healthcare providers by investing in medicines that may otherwise be unavailable. For example, without our investment, a medicine to treat hypothyroidism would have disappeared from the UK market. This is a product that simply isn’t available in many countries in the world.

    We aspire to be open, transparent and collaborative with all our stakeholders, communicating with the NHS/DHSC to provide access to our quarterly sales data (sales volumes and prices) and information on our stock holding and ability to supply.

    We help CCGs optimise their antibiotic prescribing, in the UTI therapy area, raising the profile of AMR, and the awareness of and alignment with PHE/NICE guidelines.

  • Approx. 10 percent of our niche generic medicines in the UK have had new strengths and formulations launched recently to meet patient needs and provide greater choice for prescribers.

    We are proud to help support healthcare systems around the world. In the UK, we provide a number of extremely low volume medicines supporting very niche patient groups – these are often critical medicines that require significant investment from us, to be able to continue to make them available. We do it because we are focused on serving the needs of patients and healthcare professionals with continued access to high quality, niche established medicines.

We have a proud heritage and successful track record of business and product acquisitions and company assets around the world, including BNM in Australia, Focus Pharmaceuticals in the UK, and Abcur in the Nordics.


At ADVANZ PHARMA, we have been supplying and developing niche established medicines for decades and have a rich heritage of acquiring and investing in these medicines so that patients who need them can continue to get them.


Corporate Governance

ADVANZ PHARMA is committed to conducting its business ethically and in compliance with all applicable laws, regulations, guidelines, and policies. ADVANZ PHARMA has established and implemented a Code of Conduct (the “Code”), which sets forth ADVANZ PHARMA's commitment to ethical business conduct.

  • Compliance Officer

    The Compliance Officer is responsible for overseeing the administration and implementation of ADVANZ PHARMA’s compliance program and will report at least quarterly to the Compliance Committee. The Compliance Officer has authority to direct and implement compliance-related changes and to determine the corporate response to compliance-related matters.

  • Compliance Committee

    ADVANZ PHARMA has established a Compliance Committee and the committee meets on a quarterly basis. The Compliance Committee is responsible for ensuring the implementation and effectiveness of the Compliance Program, and to provide advice and support to the Compliance Officer.

  • Compliance Policies

    ADVANZ PHARMA policies and procedures were developed to ensure that interactions with healthcare professionals are appropriate, ethical, and consistent with applicable laws and standards. ADVANZ PHARMA expects its employees to comply with the compliance program, its Code of Conduct, policies, procedures, and all applicable laws. Employees must annually acknowledge their responsibility and commitment to conduct ADVANZ PHARMA’s business consistent with these standards and to report to real or suspect violations. Employees who violate these standards are subject to appropriate disciplinary action, up to and including termination. ADVANZ PHARMA’s policies prohibit retaliation against any employee for making a good faith report.

  • Communicating Compliance & Policies

    ADVANZ PHARMA is committed to an environment in which open communications are encouraged, including questions or concerns about the compliance program. Employees are required to report any activity or individual that is suspect or in violation of the compliance program. Employees may contact direct managers, the Chief Executive Officer, the Chief Financial Officer, the Compliance Officer or the Compliance Committee at compliance@advanzpharma.com or they may use the Compliance Hotline by calling 855-562-5982. The Hotline is available 24 hours a day/7 days a week to allow confidential and anonymous reporting.

  • Monitoring, Auditing & Investigations

    The compliance program includes activities designed to monitor and audit compliance with ADVANZ PHARMA policies and procedures. The Compliance Officer oversees monitoring and auditing through an audit plan, including internal and external auditing activities. The Compliance Officer works with relevant resources to evaluate audit findings and ensure the implementation of any corrective action. The Compliance Officer (or designee) reviews and evaluates concerns to determine the required investigative response.

  • Corrective Action & Discipline

    If it is determined that noncompliant conduct has occurred, appropriate parties are responsible for corrective and/or disciplinary actions. ADVANZ PHARMA’s disciplinary actions may include the following: termination; disciplining any involved employee(s); disciplining supervisor for failure to monitor employees appropriately. ADVANZ PHARMA’s corrective and preventative actions may include: revising the compliance program, policies, and/or procedures; revising the role of the Compliance Committee; increased auditing and monitoring; revising the training program.

  • Updating the Compliance programme

    As ADVANZ PHARMA evolves as a company and as regulations change, it may amend its compliance program. The Compliance Committee reviews and approves all suggested changes. The Compliance Officer shall be responsible for communicating changes in the compliance program to employees.

  • California Compliance Law Declaration

    As part of ADVANZ PHARMA’s continuing commitment to corporate compliance, ADVZ declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Program as mandated by this California law. To the best of our knowledge, as of November 1, 2017, ADVZ believes that it is in compliance with its Comprehensive Compliance Program and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402.
    Additionally, to comply with California law, ADVZ has established a maximum annual aggregate dollar limit of $1,500 for gifts, promotional materials or activities provided to California health care professionals. This dollar limit represents a spending cap, not a goal or average, and typically the amount spent per physician is anticipated to be substantially less than this maximum amount.
    For questions about our Comprehensive Compliance Program or to obtain a copy, please contact us at compliance@advanzpharma.com.

  • Advanz Pharma AGM 2019

    Form of Proxy

    Circular

    Notice of Meeting

    Voting Instruction Form

    Financial Statements and Management's Discussion and Analysis

Our Leadership Team

  • Graeme Duncan

    Chief Executive Officer —

    Graeme has more than 20 years of healthcare and life sciences experience including senior commercial, strategy and general management roles at GlaxoSmithKline, IVAX Pharmaceuticals, and Healthcare at Home. Prior to accepting the Chief Executive Officer role at ADVANZ PHARMA, Graeme previously served as President of ADVANZ PHARMAs International segment since January 2016. Prior to his role as President, he was Managing Director for ADVANZ PHARMA's International segment.

  • Adeel Ahmad

    Chief Financial Officer —

    Adeel brings over 20 years of experience in the pharmaceutical, distribution, telecommunications and accounting industries. Prior to becoming the Chief Financial Officer of ADVANZ PHARMA, Adeel was CFO of the Company’s International segment, and before that, Vice President, Finance and Controller of the Company. Prior to joining the company in 2013, Adeel was the Chief Financial Officer of the Indian operations of Ingram Micro Mobility (formerly BrightPoint), based in New Delhi, India, from February 2012 to May 2013. Prior to his role at BrightPoint, Mr. Ahmad held several finance roles of increasing responsibility with Nortel Networks from 2003 to 2012, based in Brampton, Ontario, Canada; Seoul, South Korea; and Beijing, China. Adeel started his career in an audit function with Deloitte LLP in Toronto. He holds a B. Comm from the University of Toronto and an MBA from the Ivey School of Business, University of Western Ontario.

  • Karl Belk

    Chief Operations Officer —

    Karl has more than 30 years of experience in manufacturing, packaging, supply chain and distribution, and 20 years in senior management and leadership positions including his role as Operations Director for Teva. As Chief Operations Officer for ADVANZ PHARMA, Karl leads all operations functions globally, including scientific affairs (medical, regulatory and quality), supply (supply chain and supplier alliance management), new product introductions and technical operations.

  • Guy Clark

    Chief Corporate Development Officer —

    Guy brings to ADVANZ PHARMA more than 25 years of experience in the pharmaceutical industry, including previous senior roles at Glenmark Pharmaceuticals and IVAX Pharmaceuticals. Most recently, he served as Chief Strategy Officer at AMCo Pharmaceuticals from 2013 to 2015. As Chief Corporate Development Officer for ADVANZ PHARMA, Guy focuses on leading the company’s corporate development initiatives including M&A, strategy formulation & implementation and expanding its pipeline of medicines.

  • Simon Tucker

    Chief Commercial Officer, Established Products Unit —

    Simon started his pharmaceutical career as a Medical Representative with Pfizer Ltd in the UK. In 2000 he joined Goldshield and held various International Regional Management positions in the Middle East, Asia and Europe. He then joined the International division of Stiefel Laboratories with particular focus on the Middle East and Africa. Simon joined Amdipharm in 2006 and was instrumental in establishing its Latin American business. In 2011, he became the Director of Alliance Management and in 2013 he was appointed International Commercial Director. As President, International & North America Simon leads our commercial operations in these regions.

  • Paul Burden

    Chief Commercial Officer, Strategic Growth Unit —

    Paul joined ADVANZ PHARMA from Teva in September 2016 in the role of Vice President UK&I Commercial. His diverse commercial career spans 20 years and also includes marketing and commercial strategy roles at Smiths Medical Systems, IVAX Pharmaceuticals, Merck Generics (Mylan) and Arrow Generics (Watson Pharmaceuticals). In 2009 Paul moved into consultancy working as a Director at Fleishman-Hillard (an Omnicom communications consultancy), where he managed international communications programmes for Bristol Myers Squibb and Philips. In 2013, he joined Teva, where he had board level responsibility for the largest generics business in the UK. As President, UK & Ireland and Global Corporate Communications, Paul leads our commercial operations in the region, in addition to leading our Corporate Communications function.

  • Robert Sully

    General Counsel —

    Rob is an experienced General Counsel and corporate lawyer. He worked in London for 11 years for an international law firm before joining AMCo in 2011. As General Counsel during 2011-2016 he ran the legal, company secretarial and corporate communications teams. He was at the forefront of all M&A and he led all post-acquisition integration projects, including the merger of Amdipharm and Mercury Pharma during 2012-13 to create AMCo, and the integrations of Abcur (Sweden), Focus Pharma (UK), Primegen (UK) and BnM (Australia) into AMCo in 2013-2015. He led the integration of the International and North American divisions of Advanz Pharma in 2015-2016 and managed the Group’s regulatory disputes. He was appointed as Global General Counsel in 2018.

  • Elmar Schnee

    Non-Executive Chairman —

    Mr. Schnee has more than 30 years of senior-level pharmaceutical experience including CEO at Merck Serono, and Managing Director at UCB Pharma. He is currently serving on the board of Jazz Pharmaceuticals, and as the Chairman of Santhera Pharmaceuticals and Calliditas Therapeutics.

  • Graeme Duncan

    Director —

    Graeme has more than 20 years of healthcare and life sciences experience including senior commercial, strategy and general management roles at GlaxoSmithKline, IVAX Pharmaceuticals, and Healthcare at Home. Prior to accepting the interim Chief Executive Officer role at ADVANZ PHARMA, Graeme previously served as President of ADVANZ PHARMA’s International segment since January 2016. Prior to his role as President, he was Managing Director for ADVANZ PHARMA’s International segment.

  • Florian Hager

    Director —

    Florian is a Principal at GSO Capital Partners based in London, England. He is involved in both debt and equity investments across a wide variety of industries with a specific focus on special situations. Before joining GSO Capital Partners, Florian worked in Blackstone’s Restructuring & Reorganization Group where he advised debtors and creditors on in-court and out-of-court restructurings. Prior to Blackstone, he worked at Lehman Brothers and Nomura International in London where he was involved in numerous transactions across the industrial and technology sectors, including mergers and acquisitions, initial public offerings and leveraged buyouts.

  • Robert Manzo

    Director —

    Robert co-founded Policano and Manzo, LLC, a consulting firm specialising in providing financial services to distressed companies and their lenders. In 2000, he sold his firm to FTI Consulting, Inc., a global business advisory firm where he held the position of senior managing director through 2005. Since 2006, Robert has been a private investor and serves on a number of public and private company boards.

  • Frances Cloud

    Director —

    Frances Cloud has more than 20 years of experience in the pharmaceutical sector, including her time working as an analyst and investment banker for a number of banks, including Nomura International, IMI Securities and Swiss Bank Corporation (now part of UBS). She established Pharmacloud Research in 2009 to focus on covering the generic medicine industry in Europe, India and the MENA region. Pharmacloud provides specialist advice and consultancy to the pharmaceutical industry and financial investors, including commercial due diligence on off-patent products.

  • Maurice Chagnaud

    Director —

    Maurice Chagnaud has more than 25 years of experience in the pharmaceutical sector including senior and leadership roles at Merck KgAa, Merck Generics, Teva, Lupin and Polpharma. Geographically, he has extensive experience working in France, Italy, Germany, Central and Eastern Europe, Russia and the Commonwealth of Independent States, where he managed the commercial activities of generic, OTC and speciality product portfolios.

  • Adeel Ahmad

    Interim Director —

    Mr. Ahmad has more than 20 years of experience in the pharmaceutical, distribution, telecommunications and accounting industries. Prior to becoming the CFO of ADVANZ PHARMA in June 2018, Mr. Ahmad was CFO of the Company's International segment, and before that, Vice President, Finance and Controller of the Company.

Contact